跳至主要内容
临床试验/NL-OMON53411
NL-OMON53411已完成不适用

A Multicenter, Cross-sectional Study to Characterize the Distribution of Lipoprotein(a) Levels Among Patients With Documented History of Atherosclerotic Cardiovascular Disease (ASCVD) - 20210057

Amgen0 个研究点目标入组 1,500 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Amgen
入组人数
1,500

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

入选标准

  • 101. Subject has provided informed consent prior to initiation of any study
  • specific activities/procedures.
  • 102. Age 18 to 85 years.
  • 103. History of ASCVD as demonstrated by either:
  • a) MI (presumed type 1)
  • b) PCI (with high-risk features) with at least 1 of the following:
  • - Age > 65 years
  • -Diabetes mellitus
  • - History of ischemic stroke
  • - History of peripheral arterial disease
  • - Residual stenosis >= 50%
  • - Multivessel PCI (ie, >= 2 vessels, including branch arteries)
  • See section 5.1 of the protocol.

排除标准

  • 201. Subjects known to be currently receiving investigational drug in a
  • clinical study that is anticipated to last > 1 year
  • 202. Known Lp(a) value < 90 mg/dL (if measured in mass) or < 200 nmol/L (if
  • measured in molar).
  • 203. Subject has a diagnosis of end-stage renal disease or requires dialysis
  • 204. Poorly controlled (glycated hemoglobin [HbA1c] > 10%) diabetes mellitus
  • (type 1 or type 2).
  • 205. Subject is receiving or has received lipoprotein apheresis to reduce Lp(a)
  • within 3 months prior to enrollment.
  • 206. Known uncontrolled or recurrent ventricular tachycardia in the past 3
  • months prior to enrollment.
  • 207. Known malignancy (except non-melanoma skin cancers, cervical in situ
  • carcinoma, breast ductal carcinoma in situ, or stage 1 prostate carcinoma)
  • within the last 5 years prior to enrollment.
  • 208. Known history or evidence of clinically significant disease (eg,
  • respiratory, gastrointestinal, or psychiatric disease) or unstable disorder or
  • biomarker that, in the opinion of the investigator(s), would result in life
  • expectancy < 5 years.
  • 209. Known hemorrhagic stroke.
  • See section 5.2 of the protocol.

研究者

发起方
Amgen

相似试验

A Multicenter, Cross-sectional Study to Characterize... | 临床试验